{"id":"cggv:4b68b9e6-cc1a-44ee-8860-319bc131e948v1.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Moderate","contributions":[{"id":"cggv:4b68b9e6-cc1a-44ee-8860-319bc131e948_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10081","date":"2024-06-28T17:54:35.875Z","role":"Publisher"},{"id":"cggv:4b68b9e6-cc1a-44ee-8860-319bc131e948_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10081","date":"2024-06-20T17:00:00.000Z","role":"Approver"}],"curationReasons":{"id":"cg:NewCuration"},"earliestArticle":{"id":"https://pubmed.ncbi.nlm.nih.gov/32865517","type":"dc:BibliographicResource","dc:abstract":"Human natural killer cell deficiency (NKD) arises from inborn errors of immunity that lead to impaired NK cell development, function, or both. Through the understanding of the biological perturbations in individuals with NKD, requirements for the generation of terminally mature functional innate effector cells can be elucidated. Here, we report a cause of NKD resulting from compound heterozygous mutations in minichromosomal maintenance complex member 10 (MCM10) that impaired NK cell maturation in a child with fatal susceptibility to CMV. MCM10 has not been previously associated with monogenic disease and plays a critical role in the activation and function of the eukaryotic DNA replisome. Through evaluation of patient primary fibroblasts, modeling patient mutations in fibroblast cell lines, and MCM10 knockdown in human NK cell lines, we have shown that loss of MCM10 function leads to impaired cell cycle progression and induction of DNA damage-response pathways. By modeling MCM10 deficiency in primary NK cell precursors, including patient-derived induced pluripotent stem cells, we further demonstrated that MCM10 is required for NK cell terminal maturation and acquisition of immunological system function. Together, these data define MCM10 as an NKD gene and provide biological insight into the requirement for the DNA replisome in human NK cell maturation and function.","dc:creator":"Mace EM","dc:date":"2020","dc:title":"Human NK cell deficiency as a result of biallelic mutations in MCM10."},"evidence":[{"id":"cggv:4b68b9e6-cc1a-44ee-8860-319bc131e948_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:4b68b9e6-cc1a-44ee-8860-319bc131e948_ar_el","type":"EvidenceLine","specifiedBy":"GeneValidityOverallAutosomalRecessiveVariantEvidenceCriteria","strengthScore":5},{"id":"cggv:67d9d439-07aa-48f0-b786-94cd2c83957e_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:67d9d439-07aa-48f0-b786-94cd2c83957e","type":"Proband","ageType":"AgeAtOnset","ageUnit":"WeeksGestation","ageValue":20,"allele":[{"id":"cggv:16f0841b-5b13-44f9-b78e-d9537409e9d9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018518.5(MCM10):c.236del (p.Gly79GlufsTer6)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2499220195"}},{"id":"cggv:a15618d5-f273-452d-8ace-9502b088413f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018518.5(MCM10):c.764+5G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5411298"}}],"detectionMethod":"Exome sequencing of parents and proband, initially assessing cardiomyopathy associated genes without yield, then gene agnostic trio analysis undertaken with genome sequencing of the third affected fetus","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Histology of spleen showed autolyzed tissue with no specific pathological features, myocardial histology showed enlarged myofiber nuclear size and endocardial fibroelastosis consistent with cardiomyopathy, intrauterine death at 27 weeks, karyotyping on amniotic fluid normal\n","phenotypes":["obo:HP_0034241","obo:HP_0030718","obo:HP_0001789","obo:HP_0000778","obo:HP_0010451","obo:HP_0001698","obo:HP_0001712","obo:HP_0001723"],"previousTesting":true,"previousTestingDescription":"Routine 12 week antenatal scan normal","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":[{"id":"cggv:caa07097-f154-460d-9003-beba8609d31b_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:a15618d5-f273-452d-8ace-9502b088413f"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/33712616","type":"dc:BibliographicResource","dc:abstract":"Minichromosome maintenance protein 10 (MCM10) is essential for eukaryotic DNA replication. Here, we describe compound heterozygous MCM10 variants in patients with distinctive, but overlapping, clinical phenotypes: natural killer (NK) cell deficiency (NKD) and restrictive cardiomyopathy (RCM) with hypoplasia of the spleen and thymus. To understand the mechanism of MCM10-associated disease, we modeled these variants in human cell lines. MCM10 deficiency causes chronic replication stress that reduces cell viability due to increased genomic instability and telomere erosion. Our data suggest that loss of MCM10 function constrains telomerase activity by accumulating abnormal replication fork structures enriched with single-stranded DNA. Terminally-arrested replication forks in MCM10-deficient cells require endonucleolytic processing by MUS81, as MCM10:MUS81 double mutants display decreased viability and accelerated telomere shortening. We propose that these bi-allelic variants in MCM10 predispose specific cardiac and immune cell lineages to prematurely arrest during differentiation, causing the clinical phenotypes observed in both NKD and RCM patients.","dc:creator":"Baxley RM","dc:date":"2021","dc:title":"Bi-allelic MCM10 variants associated with immune dysfunction and cardiomyopathy cause telomere shortening."}},{"id":"cggv:f709313b-9164-4645-b9de-35647ee1b90b_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:16f0841b-5b13-44f9-b78e-d9537409e9d9"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/33712616"}],"rdfs:label":"Baxley proband"},{"id":"cggv:f709313b-9164-4645-b9de-35647ee1b90b","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:f709313b-9164-4645-b9de-35647ee1b90b_variant_evidence_item"},{"id":"cggv:f709313b-9164-4645-b9de-35647ee1b90b_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Frameshift causing premature stop which undergoes NMD. Not reported in gnomAD. HCT116 MCM10+/- cell line with regularly interspersed palindromic repeat-CRISPR-Cas9 used to introduce frameshift mutaion causing premature stop in exon 3 to model this variant. Reduced protein expression and proliferation seen. "}],"strengthScore":2},{"id":"cggv:caa07097-f154-460d-9003-beba8609d31b","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:caa07097-f154-460d-9003-beba8609d31b_variant_evidence_item"},{"id":"cggv:caa07097-f154-460d-9003-beba8609d31b_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Donor splice site variant - hypomorphic allele and causes a more severe reduction in MCM10 function than the hypomorphic variant reported in Mace proband. Variant alters exon 6 spice donor sequence, predicted to decrease efficiency of splice donor by half and likely produces reduced amount of wild-type MCM10 transcript. RNA analysis suggests splicing of exon 5 to 7 excluding 6, changing the open read frame and introducing a premature stop causing truncation prior to nuclear localization sequence. Cryptic spice acceptor in exon 7 with reduced functional score (carrying internal deletion AA 198-282). Altered biochemical behaviour of terminally truncated mutant deltaN27 vs hMCM10-ID - partially aggregated and eluted in void volume, decreased thermal stability and thermal denaturation."}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:c67348d2-1e95-40b9-b211-7988d404739d_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:c67348d2-1e95-40b9-b211-7988d404739d","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":16,"allele":[{"id":"cggv:817c7231-133b-4b0b-8c7a-91365e014c84","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018518.5(MCM10):c.1744C>T (p.Arg582del)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA376035109"}},{"id":"cggv:7f34da7e-830e-4678-b6bb-ff534bbaf89c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018518.5(MCM10):c.1276C>T (p.Arg426Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5411472"}}],"detectionMethod":"Exonic portions of genomic DNA were captured with custom VCrome probes (52 Mb;\nRoche NimbleGen Inc.) and DNA was sequenced using Illumina HiSeq 2500 equipment\n(Illumina). ","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Profoundly reduced NK cell numbers\nOver-representation of CD56bright NK cells\nReduced CD4 and CD8 T cells\nReduced memory and effector T cells\nReduced T cell activation to PHA, normal response to PMA and CD3\nElevated triglycerides","phenotypes":["obo:HP_0011900","obo:HP_0012190","obo:HP_0002014","obo:HP_0032557","obo:HP_0001433","obo:HP_0040218","obo:HP_0003281","obo:HP_0001945","obo:HP_0010976","obo:HP_0032247"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":[{"id":"cggv:c20f0dfc-33f9-4834-90d5-e4fd6f988c97_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:7f34da7e-830e-4678-b6bb-ff534bbaf89c"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/32865517"},{"id":"cggv:8dc49744-76e7-4688-a82c-918f04049753_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:817c7231-133b-4b0b-8c7a-91365e014c84"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/32865517"}],"rdfs:label":"Mace proband"},{"id":"cggv:8dc49744-76e7-4688-a82c-918f04049753","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:8dc49744-76e7-4688-a82c-918f04049753_variant_evidence_item"},{"id":"cggv:8dc49744-76e7-4688-a82c-918f04049753_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Premature stop codon at end of exon 13, located N-terminally to previously reported C-terminal domain required for nuclear localisation in multicellular eukaryotes. Predicted to undergo nonsense-mediated decay. Protein expressed at predicted MW for full length MCM10 demonstrated by immunblotting of lysates from patient primary dermal fibroblasts, suggesting mRNA degraded by NMD without production of truncated protein. Significantly impaired nuclear localisation of MCM10 in turbo-GFP-MCM10-R582X transfected 293T cells. "}],"strengthScore":2},{"id":"cggv:c20f0dfc-33f9-4834-90d5-e4fd6f988c97","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:c20f0dfc-33f9-4834-90d5-e4fd6f988c97_variant_evidence_item"},{"id":"cggv:c20f0dfc-33f9-4834-90d5-e4fd6f988c97_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Missense variant allele in exon 10 inherited from father. Predicted to be disease causing by MutationTaster (0.99) and PolyPhen2 (1.0), CADD 24.3, conserved across all species. Nuclear MCM10 localisation not affected MCM10 in turbo-GFP-MCM10-R426C transfected 293T cells. hTERT-RPE-1  cell lines homozygous for R426C retained 80% growth compared to WT."}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":5},{"id":"cggv:4b68b9e6-cc1a-44ee-8860-319bc131e948_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:4b68b9e6-cc1a-44ee-8860-319bc131e948_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:5aa45605-3002-4411-81ae-bf0cfdd8e8ef","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:d2a8d9f5-d5ab-4c7c-a089-60a8e777e9ca","type":"Finding","demonstrates":{"id":"cg:GeneExpressionA"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/25613900","type":"dc:BibliographicResource","dc:abstract":"Resolving the molecular details of proteome variation in the different tissues and organs of the human body will greatly increase our knowledge of human biology and disease. Here, we present a map of the human tissue proteome based on an integrated omics approach that involves quantitative transcriptomics at the tissue and organ level, combined with tissue microarray-based immunohistochemistry, to achieve spatial localization of proteins down to the single-cell level. Our tissue-based analysis detected more than 90% of the putative protein-coding genes. We used this approach to explore the human secretome, the membrane proteome, the druggable proteome, the cancer proteome, and the metabolic functions in 32 different tissues and organs. All the data are integrated in an interactive Web-based database that allows exploration of individual proteins, as well as navigation of global expression patterns, in all major tissues and organs in the human body.","dc:creator":"Uhl√©n M","dc:date":"2015","dc:title":"Proteomics. Tissue-based map of the human proteome."},"rdfs:label":"UniProt - Human Protein Atlas"}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"cggv:ff4363b7-2174-4750-ae52-a30c8d262244","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:555559b6-ebf5-430f-ad6a-7bf64c42543b","type":"Finding","demonstrates":{"id":"cg:BiochemicalFunctionB"},"dc:description":"Restrictive cardiomyopathy in Baxley proband, and NK cell deficiency seen in Mace proband associated with arrest in cell development. Significantly reduced NK cells with arrest at stage 4 without attainment of mature stage 5 NK cells.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/15494305","type":"dc:BibliographicResource","dc:abstract":"Mcm10 is a conserved eukaryotic DNA replication factor whose function has remained elusive. We report here that Mcm10 binding to replication origins in budding yeast is cell cycle regulated and dependent on the putative helicase, Mcm2-7. Mcm10 is also an essential component of the replication fork. A fraction of Mcm10 binds to DNA, as shown by histone association assays that allow for the study of chromatin binding in vivo. However, Mcm10 is also required to maintain steady-state levels of DNA polymerase-alpha (polalpha). In temperature-sensitive mcm10-td mutants, depletion of Mcm10 during S phase results in degradation of the catalytic subunit of polalpha, without affecting other fork components such as Cdc45. We propose that Mcm10 stabilizes polalpha and recruits the complex to replication origins. During elongation, Mcm10 is required for the presence of polalpha at replication forks and may coordinate DNA synthesis with DNA unwinding by the Mcm2-7 complex.","dc:creator":"Ricke RM","dc:date":"2004","dc:title":"Mcm10 regulates the stability and chromatin association of DNA polymerase-alpha."},"rdfs:label":"Budding yeast with MCM10-9Myc"}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"cggv:a26b5371-7bcf-4f03-b51e-dbcfba287a54","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:d43d003b-3976-4e27-901c-b7f4a8b2bbd5","type":"Finding","demonstrates":{"id":"cg:BiochemicalFunctionB"},"dc:description":"Cell cycle defect also seen in patient cells (PMID: 32865517)","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15494305","rdfs:label":"MCM10-TD strain"}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.5},{"id":"cggv:4b68b9e6-cc1a-44ee-8860-319bc131e948_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:14bdfc48-9d32-4354-a349-7cbb01eb869f","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:a573274c-20bf-4f5a-b6e7-79e66bfa9800","type":"FunctionalAlteration","dc:description":"Increase in cells with abnormal morphology and multiple enlarged/pyknotic nuclear (reduced viability), late passage increased genomic instabliity, acquired chrommosomal rearrangements overlapping with common fragile sites. Shorter telomere at early passage and eroded overtime.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33712616","rdfs:label":"Late passage HCT116 MCM10+/-"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"cggv:c76c391b-4b0d-4c8b-ab8b-b36f162103a8","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"cggv:928da5d0-7956-4983-b312-e92846c6cc10","type":"FunctionalAlteration","dc:description":"At increased NaCl concentration MCM10 more tightly associated with chromatin in patient-derived cells vs healthy control suggesting aberrant cell cycle dynamics.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32865517","rdfs:label":"SV-40 large T Ag transformed primary dermal fibroblasts"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"cggv:e7379084-0353-48da-a0fa-cb758dd7b851","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"cggv:2337c667-637a-4141-a402-53b4ddda1b8a","type":"FunctionalAlteration","dc:description":"Significantly higher frequency of yH2AX foci in patient vs healthy donor fibroblasts including intensity and area of signal in the nucleus. Increased nuclear area in patient cells via DAPI staining, suggesting dysregulation of cell cycle and increased replication stress. Increased number of cells in S phase (reduced G2/M) by BrdU and 7-AAD analysis of cell cycle. Findings suggest cell cycle defects and replication stress.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32865517","rdfs:label":"Patient fibroblasts yH2AX, nuclear area and cell cycle"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":2},{"id":"cggv:4b68b9e6-cc1a-44ee-8860-319bc131e948_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:554748fd-a334-4e33-a476-4e1c43287b72","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"cggv:d24fc687-8bbe-465b-a86b-592330c3441d","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Similar reduction in mature NK cells observed","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32865517","rdfs:label":"In vitro MCM10-KD NK cells from CD34+ precursors"}],"specifiedBy":"GeneValidityCellCultureModelOrganismCriteria","strengthScore":1},{"id":"cggv:d8a1e0ab-e5a6-40e8-bbc4-5905ac4d63c3","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:2436da4e-633f-4c0f-94fc-76b2aa672db2","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Mouse model recapitulates NK cell immunophenotye of CD56bright (stage 4) NK cells seen in affected human, and also markers of accelerated DNA damage.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32865517","rdfs:label":"Patient derived-iPS cells in humanised mouse model"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":3}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Moderate","sequence":8533,"specifiedBy":"GeneValidityCriteria10","strengthScore":11,"subject":{"id":"cggv:32fb1f57-c249-4528-a943-c127c464bfd0","type":"GeneValidityProposition","disease":"obo:MONDO_0030266","gene":"hgnc:18043","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","dc:description":"MCM10 was first reported in relation to immunodeficiency 80 with or without congenital cardiomyopathy (MONDO: 0016587) by Mace et al in 2020 (PMID: 32865517). Inheritance in all reported cases is compound heterozygous. This condition is characterized by early onset disease profound NK cell deficiency with impaired maturation, T and B cell lymphopenia and disseminated cytomegalovirus infection, as well as antenatal restrictive cardiomyopathy with thymic and splenic hypoplasia. Evidence supporting this gene-disease relationship includes case-level and experimental data. Of the 4 reported cases, the first presented age 16 months and succumbed to overwhelming CMV age 24 months, with compound heterozygous mutations (non-sense and missense) (PMID: 32865517). The remaining 3 were sibling identified antenatally all experienced perinatal mortality with compound heterozygous mutations (non-sense and cryptic splice acceptor) (PMID: 3371261). Both parents of each proband were healthy heterozygotes for a single variant, suggesting necessity of biallelic variants to cause disease.\n\nThis gene-disease relationship is supported by biochemical function, expression studies, functional assays, a cell culture and a mouse model (PMIDs:15494305, 25613900, 33712616, 32865517). In healthy subjects, MCM10 is a conserved component of the eukaryotic replisome, and promotes initiation of DNA replication through interactions with CDC45, MCM2-7 and GINS (CMG) complex. After origin firing it controls fork stability to support elongation through recruitment of DNA POL alpha-1 and PCNA and stabilizes the replisome to prevent replication stress and promote gene stability (PMID: 28218679). In budding yeast expressing tagged MCM10, Ricke et al demonstrated that MCM10 remains at replication origins until activated but is displaced only after firing (PMID: 15494305), supporting its role in DNA replication. MCM10 is highly expressed in bone marrow and lymphoid tissues (PMID: 25613900). Transformed primary patient-derived fibroblasts showed aberrant cell cycle dynamics, whilst patient fibroblasts harbor increased DNA damage, nuclear area and proportions of S phase cells, suggesting cell cycle defects and replication stress (PMID 32865517). Late passage HCT116 MCM10+/- showed genomic instability, chromosomal rearrangements at common fragile sites and shorter early passage telomeres with erosion overtime (PMID: 33712616). A CD34+ hematopoietic stem cell MCM10KD model demonstrated an NK cell maturation defect similar to the stage 4 arrest seen in the Mace proband (PMID: 32865517). Finally, a murine model reconstituted with primary patient fibroblasts reprogramed to generate iPS, demonstrated enrichment of CD56bright NK cell subset in peripheral blood and spleen with evidence of DNA damage compared to healthy controls, again recapitulating the NK cell maturation arrest seen in Mace proband (PMID: 32865517).\n\nIn summary, there is moderate evidence to support this gene-disease relationship. Whilst more evidence is needed to establish this relationship definitively, no convincing contradictory evidence has emerged. This classification was approved by the ClinGen SCID/CID GCEP on the meeting date June 20th 2024 (SOP Version 9).","dc:isVersionOf":{"id":"cggv:4b68b9e6-cc1a-44ee-8860-319bc131e948"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}